ipamorelin cjc-1295 CJC 1295 No Dac (5mg) + (10mg) Blend CJC-1295 /Ipamorelin Blend 5mg/5mg |

European Journal of Endocrinology (1998) 5

effects diminish within 2-4 weeks of continuous use Ipamorelin: Maximum Selectivity Ipamorelin was designed specifically for selective GH release: GHS-R1a Selectivity: Activates only GH-releasing pathways at the receptor No Cortisol Effect: Does not stimulate ACTH or cortisol release No Prolactin Effect: Does not affect prolactin levels Minimal Appetite Effect: Unlike other GHRPs, does not significantly increase hunger No Cardiac Activity: Lacks Hexarelin's cardiac receptor effects No Desensitization: Effects maintain with continued use Key Trade-off: Hexarelin offers maximum acute GH release but with hormonal side effects and rapid desensitization

CJC-1295 and Ipamorelin therapy are best suited for adults who want to optimize their growth hormone levels and improve body composition, energy, and recovery

This is where DAC pulls ahead in the "annoying" column